- Home
- SKYE vs BYM Comparison
SKYE vs BYM Comparison
Compare SKYE & BYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SKYE | BYM |
|---|---|---|
| Founded | 2012 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.9M | 286.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SKYE | BYM |
|---|---|---|
| Price | $0.93 | $10.91 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $14.75 | N/A |
| AVG Volume (30 Days) | ★ 299.5K | 60.2K |
| Earning Date | 11-10-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.49% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.93 | $9.30 |
| 52 Week High | $5.75 | $11.77 |
Technical Indicators
Market Signals| Indicator | SKYE | BYM |
|---|---|---|
| Relative Strength Index (RSI) | 31.56 | 47.32 |
| Support Level | $1.04 | $10.80 |
| Resistance Level | $1.27 | $10.97 |
| Average True Range (ATR) | 0.10 | 0.10 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 1.48 | 50.61 |
Price Performance
Historical ComparisonAbout SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About BYM Blackrock Municipal Income Quality Trust of Beneficial Interest
Blackrock Municipal Income Quality Trust is a closed-end municipal bond fund. Its investment objective is to provide current income exempt from U.S. federal income taxes, including the alternative minimum tax. The trust invests in various sectors such as transportation, utilities, health, education, corporate, housing, and others.